Company
Malin Corp plc
Headquarters: Dublin, Ireland
Employees: 255
CEO: Mr. Darragh Fergal Lyons
Market Cap
€166.7 Million
EUR as of Jan. 1, 2025
US$173.5 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Spain, rest of European Union, and internationally. It offers life-saving cell and gene therapies for patients with high unmet medical need; medicines to address unmet needs in cancer, infection, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis. The company also develops, manufactures, and markets injectable medications for hospital and other healthcare provider; provides drugs for protein misfolding diseases. In addition, it focuses on the therapeutics areas of autoimmune and inflammatory disease, immuno-oncology, haematology, and infectious diseases; and platform to distinguish disease-driving bacteria from the intestinal microbiota. Further, the company provides company secretarial services. Malin Corporation plc was incorporated in 2014 and is headquartered in Dublin, Ireland.
Stocks & Indices
Malin Corp plc has the following listings and related stock indices.
Stock: ISE: MLC wb_incandescent